What is the appropriate evaluation for a patient with eosinophilia and elevated alkaline phosphatase?

Evaluation of Elevated Eosinophil Count with Elevated Alkaline Phosphatase

Begin with abdominal ultrasound to exclude biliary obstruction, followed by testing for anti-mitochondrial antibodies (AMA) and anti-nuclear antibodies (ANA) to evaluate for primary biliary cholangitis (PBC), while simultaneously investigating common causes of eosinophilia including parasitic infections, medications, and allergic conditions.

Initial Imaging Assessment

Start with abdominal ultrasound as the first-line imaging modality 1. This non-invasive test identifies:

• Dilated bile ducts suggesting obstruction
• Stones or masses
• Hepatic parenchymal abnormalities

If ultrasound shows normal bile ducts but elevated alkaline phosphatase (ALP) persists, proceed to MRCP (magnetic resonance cholangiopancreatography) to evaluate for:

• Primary sclerosing cholangitis (PSC) - characterized by multifocal strictures and dilatations 1
• Small duct disease not visible on ultrasound
• Infiltrative liver processes

Critical Serologic Testing

For Cholestatic Disease

Measure gamma-glutamyl transpeptidase (GGT) alongside ALP to confirm hepatic origin of the elevated ALP, as ALP can originate from bone, intestine, or other sources 2.

Test for autoantibodies 1:

• Anti-mitochondrial antibodies (AMA) - highly specific for PBC
• Anti-nuclear antibodies (ANA), specifically sp100 and gp210 patterns

This combination is crucial because PBC can present with peripheral eosinophilia even in asymptomatic patients with or without elevated ALP 3. Four documented cases showed moderate-to-high eosinophilia as the presenting feature of early-stage PBC, with eosinophil counts normalizing after ursodeoxycholic acid treatment.

For Eosinophilia Evaluation

Exclude parasitic infections first 4:

• Stool ova and parasite examination (3 samples)
• Strongyloides serology (critical - can cause life-threatening hyperinfection if immunosuppressed)
• Schistosoma serology if travel to endemic areas
• Filarial serology only if West Africa exposure

Review medication history thoroughly 5:

• Drug-induced eosinophilia is common
• Temporal relationship between medication initiation and eosinophilia onset
• Consider drug-induced liver injury (DILI) if on immune checkpoint inhibitors 6

Assess for allergic/atopic conditions 4:

• Asthma, eczema, allergic rhinitis (most common causes in low-endemic areas)
• Eosinophilic esophagitis if dysphagia present 7, 8

Determine Eosinophilia Severity

Mild eosinophilia (0.5-1.5 × 10⁹/L): Usually secondary/reactive

• Focus on common causes: allergies, parasites, medications

Hypereosinophilia (≥1.5 × 10⁹/L): Requires comprehensive workup 4, 9

• Never explained by allergy alone 5
• Evaluate for end-organ damage (heart, lungs, CNS)
• Consider hematologic malignancies if persistent >3 months
• Refer to hematology after excluding/treating infectious causes

Special Consideration: Immune Checkpoint Inhibitor Therapy

If patient is receiving immunotherapy, elevated ALP with eosinophilia may indicate immune-mediated liver injury (ILICI) 6:

• Cholestatic ILICI can show eosinophils on liver biopsy
• ALP ≥2× baseline warrants evaluation for ILICI vs. tumor progression, biliary obstruction, bone disease
• Consider liver biopsy if diagnosis unclear or no response to corticosteroids within 4-6 weeks

When to Perform Liver Biopsy

Consider biopsy when 1, 10:

• Diagnosis remains unclear after non-invasive testing
• Suspicion for AIH/PBC overlap syndrome (transaminases persistently >100 U/L in PBC patient)
• Suspicion for PSC with inflammatory bowel disease
• Need to distinguish between competing diagnoses
• Persistent elevation despite treatment

Algorithm Summary

1. Confirm hepatic origin: Check GGT alongside ALP
2. Imaging: Ultrasound → MRCP if indicated
3. Autoantibodies: AMA, ANA (sp100, gp210)
4. Parasitic workup: Stool O&P × 3, Strongyloides serology, travel-appropriate serology
5. Medication review: Temporal relationship, consider DILI
6. Assess eosinophil level: If ≥1.5 × 10⁹/L, evaluate for end-organ damage
7. Liver biopsy: If diagnosis unclear or overlap syndrome suspected

Critical Pitfalls to Avoid

• Do not assume eosinophilia is solely allergic if AEC ≥1.5 × 10⁹/L 5
• Do not miss Strongyloides - test all patients with travel/residence in endemic areas, as hyperinfection can be fatal 4
• Do not overlook PBC - it should be in the differential for unexplained eosinophilia even without symptoms or elevated ALP 3
• Do not forget bone sources of ALP - consider Paget's disease, metastases, fractures if GGT is normal 2
• Do not delay hematology referral if hypereosinophilia persists >3 months after excluding/treating infections 4